Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 2Hyperthermia 2Breast Neoplasms 2Uveal Melanoma 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × Hyperthermia, Induced × Clear all
NCT07062055 2026-05-08

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡